FDA Considering Allowing Developers of Drugs for Deadly or Debilitating Diseases to Conduct Smaller, Faster Clinical Trials

The Paragon Report Provides Stock Research on Puma Biotechnology and BioCryst Pharmaceuticals

Marketwired

NEW YORK, NY--(Marketwire - Oct 23, 2012) - The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Puma Biotechnology Inc. (NYSE: PBYI) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).

Access to the full company reports can be found at:

www.ParagonReport.com/PBYI
www.ParagonReport.com/BCRX

Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trial, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical need. Hamburg has said that the FDA needs to take into account the needs people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs.

"A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Pew Health Group's Allan Coukell, deputy director of medical programs. "It would be good for developers, for companies and it would be good for public health."

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Puma Biotechnology is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The company on Friday was upgraded from OTC Bulletin Board to the New York Stock Exchange.

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases. The company last week reported it will acquire Presidio Pharmaceuticals in an all-stock transaction. The new company will focus on focus on oral drugs for hepatitis C and hereditary angioedema.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

View Comments